All In Biotech

Drug Trial Radar · NCT00709371

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

A Phase IIB, Multi-Center, Dose-Parallel, Randomized, Double-Blind, Monotherapy and Placebo-Controlled Safety and Efficacy Study of Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

Last checked: Nov 20, 2026Latest source record: Nov 29, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 729 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

729

Actual

Start

Jul 2008

Primary completion

Apr 2009

Study completion Jul 2009

Sponsor

Lead sponsor
Orexigen Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Jul 3, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.

Conditions

  • Obesity

Interventions

  • Zonisamide SR placebo/ bupropion SR placeboDrug

    2 placebo combination tablets twice daily for 16 weeks (maintenance period)

  • Zonisamide SR placebo/ bupropion SR 360 mg/dayDrug

    2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)

  • Zonisamide SR 120 mg/day/ bupropion SR placeboDrug

    2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)

  • Zonisamide SR 360 mg/day/ bupropion SR placeboDrug

    2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)

  • Zonisamide SR 120 mg/day/ bupropion SR 360 mg/dayDrug

    2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)

  • Zonisamide SR 360 mg/day/ bupropion SR 360 mg/dayDrug

    2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in total body weightTime frame: from baseline to 24 weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • SelfCenter, PC

    Fairhope, Alabama

  • Nutrition and Metabolic Research

    La Jolla, California

  • Center for Human Nutrition/UCD

    Denver, Colorado

  • Miami Research Associates

    Miami, Florida

  • CSRA Partners in Health, Inc.

    Augusta, Georgia

  • Radiant Research, Chicago

    Chicago, Illinois

  • Welborn Clinic

    Evansville, Indiana

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana

  • Nutrition and Weight Management Center, Boston Medical Center

    Boston, Massachusetts

  • FutureCare Studies

    Springfield, Massachusetts

  • Summit Research Network (Michigan), Inc.

    Farmington Hills, Michigan

  • Mercy Health Research

    St Louis, Missouri

  • Center for Nutrition and Metabolic Disorders, University of Nevada School of Medicine

    Reno, Nevada

  • Behavioral Medical Research

    Staten Island, New York

  • Internal Medicine Associates of Charlotte

    Charlotte, North Carolina

  • Wake Research Associates, LLC

    Raleigh, North Carolina

  • Summit Research Network (Oregon), Inc.

    Portland, Oregon

  • The Cooper Institute

    Dallas, Texas

  • Washington Center for Weight Management and Research

    Arlington, Virginia

  • Summit Research Network (Seattle), LLC.

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.